leisure time -WSS

leisure time

author：knowledge 2025-10-09 00:16:41 - browse：8

SAN DIEGO — After starting off the year with lower revenue projections than market analysts had hoped for, San Diego-based genomics giant Illumina lowered expectations again on Wednesday, forecasting annual growth of 1% compared to the previous year.

The market’s response was swift. Minutes after the company issued its press release, shares in Illumina dipped from $184.49 to below $172 during after-hours trading.

In its release, Illumina noted that it expects revenue from the company’s core business to be essentially the same this year compared to last, and that it expects revenue from Grail, the cancer diagnostics company that Illumina acquired for $8 billion in the fall of 2021, to remain in the range of $90 and $100 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Scrutiny of post

focus

hotspot

WSS

Liver decline slowed by off

Researchers test human milk's ability to repair gut microbiome

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

ASCO eve: Let’s set the table for this year's meeting

UnitedHealth argues against case alleging wrongful AI care denials

At flashy new research hub, AstraZeneca lays out ambitious growth goals

focus

leisure time

focus

Wildfire smoke exposes gaps in outdoor worker protections

Reports of telehealth's death have been greatly exaggerated

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Oral obesity drug from Viking Therapeutics hits key early target

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Study finds gene variants tied to breast cancer risk in Black women

Continuity nursing helped my family in our darkest PICU moments

Drug companies' payments and gifts affect physicians' prescribing

How to save PrEP access — and even expand it

Hundreds died while taking an arthritis drug, but nobody alerted patients

explore

Addressing health care workers' trauma can help fight burnout

Scrutiny of post

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Mass General Brigham physicians react to latest merger step

First Opinion on colorectal cancer screening: letter and response

Hundreds died while taking an arthritis drug, but nobody alerted patients

explore

focus

hotspot

focus